The estimation of anti-SARS-CoV-2 IgG antibodies is possibly the best approach to accurately establish the number of infected individuals and the seroprevalence of COVID-19 within a population. Thus, several commercial immunoassays have recently been developed. The purpose of our study was to assess the performance of five commonly used immunoassays in Greece (3 ELISA, namely Euroimmun SARS-CoV-2, GA GENERIC SARS-CoV-2 and Vircell COVID-19; and 2 chemiluminescent, namely ABBOTT SARS-CoV-2 and ROCHE Elecsys Anti-SARS-CoV-2 test) for the detection of anti-SARS-CoV-2 IgG antibodies. Sera specimens derived from 168 individuals were utilized to assess the specificity and sensitivity score of each assay. Among them, we included 99 COVID-19 patients (29 asymptomatic, 36 with symptom onset 4 to 14 days before serum sampling, and 34 with symptom initiation ≥ 15 days ago), and 69 volunteers with sera specimens collected prior to the SARS-CoV-2 outbreak and maintained at −80°C. We demonstrated that chemiluminescent immunoassays exhibit a significantly higher specificity score but a lower sensitivity, compared to ELISA immunoassays. Moreover, immunoassays detecting IgG antibodies against SARS-CoV-2 N protein instead of S protein alone are more reliable, considering both specificity and sensitivity scores. Interestingly, all asymptomatic patients displayed anti-SARS-CoV-2 IgG antibodies, confirmed by at least two immunoassays. We suggest that chemiluminescent assays could be used as screening methods for the detection of anti-SARS-CoV-2 antibodies to evaluate the possible prevalence of disease in the general population, while ELISA assays would be more reliable to evaluate, and follow-up confirmed COVID-19 patients.
【저자키워드】 COVID-19, IgG, ELISA, immunoassay, chemiluminescent, 【초록키워드】 SARS-CoV-2, S protein, Seroprevalence, Symptom, ELISA, Prevalence, immunoassays, serum, sensitivity, specificity, anti-SARS-CoV-2 antibodies, IgG antibody, Asymptomatic, anti-SARS-CoV-2 antibody, IgG antibodies, outbreak, anti-SARS-CoV-2 IgG, anti-SARS-CoV-2 IgG antibodies, sera, N protein, Greece, SARS-CoV-2 N protein, Follow-up, General population, chemiluminescent immunoassay, disease, estimation, asymptomatic patient, COVID-19 patients, ELISA assay, Chemiluminescent assay, COVID-19 patient, Abbott, best, symptom onset, infected individuals, individual, specimen, ELISA assays, screening methods, screening method, Volunteer, approach, FIVE, commercial immunoassay, collected, evaluate, demonstrated, significantly higher, number of infected, anti-SARS-CoV-2 IgG antibody, Elecsy, the SARS-CoV-2, 【제목키워드】 detection, SARS-CoV-2 IgG,